Omega-3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies

Del Gobbo Liana C, PhD\(^1\); Imamura Fumiaki, PhD\(^2\); Aslibekyan Stella, PhD\(^3\); Marklund Matti, PhD\(^4\); Virtanen Jyrki K PhD\(^5\); Wennberg Maria PhD\(^6\); Yakoob Mohammad Y, PhD\(^1\); Chiuve Stephanie E, ScD\(^7,8\); dela Cruz Luicito, PhD\(^9\); Frazier-Wood Lekki AC, PhD\(^10\); Fretts Amanda M, MPH PhD\(^11\); Guallar Eliseo, PhD\(^12\); Matsumoto Chisa, PhD MD\(^13,14\); Prem K, PhD\(^15\); Tanaka Tosh, PhD\(^16\); Wu Jason, HY PhD\(^17\); Zhou Xia PhD\(^18\); Helmer Catherine, MD, PhD\(^19,20\); Ingelsson Erik, MD, PhD\(^1,21\);; Yuan Jian-Min, MD, PhD\(^22,23\); Barberger-Gateau Pascale, PhD\(^19,20\); Campos Hannia, PhD\(^24\); Chaves Paulo HM, MD PhD\(^25\); Djoussé Luc, MD ScD\(^14\); Giles Graham G, PhD\(^9\); Gómez-Aracena Jose, PhD\(^26\); Hodge Allison M, PhD\(^9\); Hu Frank B, PhD MD MPH\(^24,27,28\); Jansson Jan-Håkan, MD PhD\(^29\); Johansson Ingegerd, PhD\(^30\); Khaw Kay-Tee, PhD MD\(^31\); Koh Woon-Puay, PhD\(^15,32\); Lemaitre Rozenn N, PhD MPH\(^33\); Lind Lars, PhD\(^34\); Luben Robert N, PhD\(^31\); Rimm Eric B, ScD\(^24,27,28\); Risérus Ulf, PhD MD\(^4\); Samieri Cecilia, PhD\(^19,20\); Franks Paul W, PhD\(^24,29,35\); Siscovick David S, MPH MD\(^36\); Stampfer Meir, DrPH MD\(^24,27,28\); Steffen Lyn M, PhD MPH\(^18\); Steffen Brian T, PhD\(^18\); Tsai Michael Y, PhD\(^37\); van Dam Rob M, PhD\(^15,24,38\); Voutilainen Sari, PhD\(^5\); Willett Walter C, DrPH MD\(^24,27,28\); Woodward Mark, PhD\(^12,17,39\); Mozaffarian Dariush, MD DrPH\(^40\), on behalf of the CHARGE Fatty acids and Outcomes Research Consortium (FORCe).

Corresponding author/reprints: Liana Del Gobbo, PhD, Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305 Phone: 857-334-1509, Fax: 617-566-7805, delgobbo@stanford.edu

Word count: 3467

\(^1\)Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305

\(^2\)Medical Research Council Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge University
3 Department of Epidemiology, University of Alabama at Birmingham School of Public Health
4 Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University
5 Institute of Public Health and Clinical Nutrition, University of Eastern Finland
6 Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University
7 Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital
8 Department of Epidemiology, Harvard T.H. Chan School of Public Health
9 Cancer Epidemiology Centre, Cancer Council Victoria, Australia
10 USDA/ARS Children’s Nutrition Research Center, Baylor College of Medicine
11 Department of Epidemiology, University of Washington
12 Department of Epidemiology, John Hopkins Bloomberg School of Public Health
13 Division of Cardiology, Tokyo Medical University
14 Division of Aging, Brigham and Women's Hospital and Harvard Medical School
15 Saw Swee Hock School of Public Health, National University of Singapore
16 Translational Gerontology Branch, National Institute on Aging
17 The George Institute for Global Health, Sydney Medical School, University of Sydney
18 Division of Epidemiology & Community Health, University of Minnesota School of Public Health
19 INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, F-33000 Bordeaux, France
20 Univ. Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, F-33000 Bordeaux, France
21 Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University
22 Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute
23 Department of Epidemiology, University of Pittsburgh Graduate School of Public Health
24 Department of Nutrition, Harvard T.H. Chan School of Public Health
25 Benjamin Leon Center for Geriatric Research and Education, Florida International University
26 Department of Preventive Medicine, Universidad de Malaga
27 Department of Epidemiology, Harvard T.H. Chan School of Public Health
28 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School
29 Department of Public Health and Clinical Medicine, Umeå University
30 Department of Odontology, Umeå University
31 Department of Public Health and Primary Care, University of Cambridge
32 Duke-NUS Graduate Medical School Singapore
31 Cardiovascular Health Research Unit, Department of Medicine, University of Washington
34 Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University
35 Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University
36 The New York Academy of Medicine
37 Department of Laboratory Medicine and Pathology, University of Minnesota
38 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore
39 The George Institute for Global Health, Nuffield Department of Public Health, Oxford University
40 Friedman School of Nutrition Science & Policy, Tufts University
Abstract

**Importance:** The role of omega-3 polyunsaturated fatty acids for primary prevention of coronary heart disease (CHD) remains controversial. Most prior longitudinal studies evaluated self-reported consumption, rather than biomarkers.

**Objective:** To evaluate biomarkers of seafood-derived eicosapentaenoic (EPA; 20:5n-3), docosapentaenoic (DPA; 22:5n-3), and docosahexaenoic acid (DHA; 22:6n-3), and plant-derived α-linolenic acid (ALA; 18:3n-3), and incident CHD.

**Data Sources:** A global consortium of 19 studies.

**Study Selection:** Available prospective (cohort, nested case-control) or retrospective studies with circulating or tissue omega-3 biomarkers and ascertained CHD.

**Data Extraction and Synthesis:** Each study conducted standardized individual-level analysis using harmonized models, exposures, outcomes, and covariates. Findings were centrally pooled using inverse-variance meta-analysis. Heterogeneity was examined by age, sex, race, diabetes, statins, aspirin, omega-6 levels, and FADS-desaturase genes.

**Main Outcome(s) and Measure(s):** Incident total CHD, fatal CHD, and nonfatal myocardial infarction (MI).

**Results:** The 19 studies comprised 16 countries, 45,637 unique individuals, and 7973 total CHD, 2781 fatal CHD, and 7157 non-fatal MI events, with omega-3 measures in plasma, phospholipids, cholesterol esters, and adipose. In continuous (per 1 standard deviation increase) multivariable-adjusted analyses, omega-3 biomarkers ALA, DPA, and DHA were associated with lower risk of fatal CHD, with RR s (95% CI): ALA 0.91(0.84-0.98), DPA 0.90(0.85-0.96), and DHA 0.90(0.84-0.96), with EPA showing a trend towards lower risk (0.91 (0.82-1.00)).
DPA, but not ALA, EPA, or DHA, was associated with lower risk of total CHD, with RR (95% CI): 0.94(0.90-0.99), 1.00(0.95-1.05), 0.94(0.87-1.02), and 0.95(0.91-1.00), respectively.

Significant associations with nonfatal MI were not evident. Associations appeared generally stronger in phospholipids and total plasma. Restricted cubic splines did not identify evidence for nonlinearity in dose-responses.

**Conclusions and Relevance:** Based on available studies of free-living populations globally, biomarker concentrations of both seafood and plant-derived omega-3s are associated with a modestly lower incidence of fatal CHD.
Introduction

Experimental studies and randomized trials support a protective effect of omega-3 polyunsaturated fatty acids (omega-3 PUFA) on coronary heart disease (CHD) risk pathways and clinical risk factors (1). Yet, key controversies remain. First, randomized trials utilizing fish oil supplements have shown mixed effects on CHD events (2-8). However, most provided supplements for a few years or less and were conducted in patients with pre-existing CHD, or at high risk and taking multiple cardiovascular drugs. Further, the background dietary intake in these trials was not usually measured, and many participants may have had adequate intake from diet alone. Thus, their generalizability and relevance for long-term effects of dietary omega-3 PUFA for primary CHD prevention are uncertain. Second, while several prior observational studies have found inverse associations between seafood-derived omega-3 PUFA and CHD death, potential effects on nonfatal myocardial infarction (MI) or total CHD are less clear (9). Most prior studies also relied on self-reported dietary questionnaires, which may produce errors or bias in recall. A handful of studies have measured objective circulating or tissue omega-3 PUFA levels (1) but such findings could be limited by publication bias. In addition, prior individual biomarker studies were generally underpowered to explore potentially relevant differences in effects depending on underlying participant characteristics, medication use, or genetic variation. Thus, uncertainties remain about effects of omega-3 PUFA on CHD.

Most studies have evaluated combined intakes or biomarker levels of long-chain omega-3 PUFA. Yet, individual omega-3 PUFA including eicosapentaenoic acid (EPA; 20:5n-3), docosapentaenoic acid (DPA; 22:5n-3), and docosahexaenoic acid (DHA; 22:6n-3) may have both shared and complementary effects (10). Similarly, the majority of prior research has
focused on seafood-derived long-chain omega-3 PUFA, and potential CHD effects of plant-derived α-linolenic acid (ALA; 18:3n-3) are far less understood (11).

To address each of these important questions, we developed a global consortium including available studies with circulating or tissue omega-3 biomarkers and ascertained incident CHD. Our aims were to evaluate the associations of individual seafood- and plant-derived omega-3 PUFA with incident total CHD, fatal CHD, and nonfatal MI. We also explored dose-response and potential heterogeneity in effects according to key underlying participant characteristics, including medication use. Our primary hypothesis was that biomarkers of long-chain omega-3 PUFA would be associated with lower risk of incident fatal CHD, but not nonfatal MI.
Methods & Statistics

Consortium formation

The Fatty acids and Outcomes Research Consortium (FORCe) is an extension of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids Working Group (12, 13), originally developed to investigate effects of genetic variation on biomarker fatty acid levels. Using direct expert contacts and by reviewing the literature, we identified large studies that had measured circulating or tissue biomarkers of omega-3 PUFA in general populations and had ascertained incident CHD. We focused on prospective (cohort, nested case-control) studies; retrospective studies were included if fatty acids were measured in adipose tissue at the time of the first event given stability of adipose measures. Studies were asked to join the consortium and participate in standardized pooled analyses of biomarker fatty acids and clinical events. Of 20 identified studies by November 2014, only 1 study declined to join the consortium (14). All cohort participants gave written informed consent according to their local guidelines. All studies received approval from ethical oversight committees.

Analysis plan

A standardized analysis protocol was developed and provided to each participating study, including harmonized definitions of populations, exposures, outcomes, covariates, effect modifiers, and methods for pooling across studies. These specific methods are detailed below. An experienced analyst from each study performed the analysis for that study using individual-level data and provided all results to the lead investigator (L.D.) in standardized electronic forms.

Population
To understand potential effects on primary prevention and minimize reverse causation, participants from each study were excluded if they had a prior history of myocardial infarction (MI), angina, coronary revascularization, or stroke. All remaining participants with measured omega-3 PUFA biomarker levels were included in the analyses.

Fatty acid ascertainment

Fatty acid biomarker concentrations were assessed in study-specific lipid compartments, including total plasma, erythrocyte and plasma phospholipids, cholesterol esters, triglycerides, and adipose tissue, all reported as weight percent of total fatty acids. Details of fatty acid measurement methods for each study are provided in the Online-Only Supplement (pg 27).

Assessment of CHD

We evaluated total incident CHD, defined as fatal or nonfatal MI, CHD death, or sudden cardiac death; nonfatal MI, generally defined as chest pain with abnormal cardiac enzyme concentrations or serial electrocardiogram changes; and fatal CHD, defined as fatal MI, CHD death, or sudden cardiac death. Details of the methods for assessing and defining these outcomes in each study are provided in eTable 1. We excluded soft CHD endpoints (e.g., angina, revascularization) to minimize bias in ascertainment of these events.

Covariates

Covariates were standardized across studies based on pre-specified, harmonized definitions and categorizations, including age (continuous), sex (male, female), race (Caucasian, black, and by other study-specific subgroups, if available), clinical center, if applicable (study-
specific categories), body mass index (continuous), education (less than high school graduate, high school graduate, some college or vocational school, college graduate), smoking (current, former, never; or current vs. not current, if former not assessed), physical activity (quartiles of metabolic equivalents (METs); or if METs unavailable, four categories of physical or leisure activity as defined in the study), alcohol intake (none, 1-6 drinks/week, 1-2 drinks/day, >2 drinks/day; with 14 grams alcohol=1 standard drink), diabetes mellitus (yes, no; defined as treatment with oral hypoglycemic agents, insulin, or fasting glucose; or study-specific definitions otherwise); treated hypertension (yes, no; defined as treatment with anti-hypertensive drugs; diagnosed hypertension otherwise), treated hypercholesterolemia (yes, no; defined as treatment with lipid-lowering drugs; or diagnosed hypercholesterolemia otherwise), regular aspirin use [yes, no; categorized as 3+ times/week], and biomarker concentrations of omega-6 PUFA linoleic acid (LA; 18:2n-6), arachidonic acid (AA; 20:4n-6), and total trans fatty acids (each continuous). For categorical variables, missing covariate data were included as an indicator category.

Statistical analysis and pooling

Standardized study-specific analyses were performed for each study using individual-level data. Due to variability in the total number of fatty acids assessed across the different assays (from 12 to 58), and to permit comparison and pooling of findings across the different biomarker compartments, each fatty acid was analyzed continuously per 1 standard deviation increase.

For prospective cohorts, Cox proportional hazards models estimated the hazard ratio for incident total CHD, nonfatal MI, and fatal CHD, with follow-up from the date of biomarker
measurement to date of event, end of follow-up, loss to follow-up, or death, whichever occurred first. For prospective and retrospective matched case-control studies, conditional logistic regression was used to estimate the hazard ratio (if matched on time to event) or odds ratio. All analyses used robust standard errors.

For pooled meta-analyses, hazard ratios and odds ratios were considered to approximate relative risks (RRs). Meta-analysis was performed using random effects models using the method of DerSimonian & Laird, with the estimate of heterogeneity obtained from the Mantel-Haenszel model (15). Results were first pooled separately for each biomarker compartment and then pooled together. If more than one biomarker had been measured in a given study, main results included the biomarker which might best represent diet: for long-chain omega-3s, total plasma/serum > phospholipids (erythrocyte or plasma) > adipose > other; and for ALA, adipose > total plasma/serum > phospholipids (16).

To assess potential non-continuous relationships, we also evaluated study-specific quintiles for each biomarker compartment, performing meta-analysis within each quintile and comparing each quintile-specific pooled result to the first quintile. To statistically test potential nonlinear dose-responses, we performed multivariate meta-regression, modeling restricted cubic splines (17). These analyses evaluated total plasma and phospholipids; cholesterol esters and adipose tissue fatty acids were not evaluated using splines due to fewer numbers of studies in these compartments.

Overall heterogeneity was assessed using the $I^2$ statistic, with heterogeneity considered low if $I^2 < 35\%$. Heterogeneity by pre-specified subgroups was evaluated by pooling individual study results based on defined strata, including age (< 60, ≥ 60 years), sex (male, female), race/ethnicity (Caucasian, Black, Hispanic, Chinese), LA and AA biomarker concentrations (< or
≥ median value in each study), type 2 diabetes (yes, no), statin use (yes, no), regular aspirin use (yes, no), year of biomarker sampling (<2000, ≥2000), and (for ALA) EPA+DPA+DHA biomarker concentration (< or ≥ median value in each study). Effect estimates in each study-specific strata were pooled, and statistical significance of differences between subgroups of potential sources of heterogeneity was assessed using meta-regression. In 7 studies with available genetic data, we also examined potential interaction by variants in FADS desaturase genes (rs174546, rs968567) (13), pooling study-specific estimates using an additive genetic model (Online-Only Supplement pg 39). Within each study, interaction terms for each SNP were constructed as a cross-product term of the omega-3 PUFA biomarker (continuous) by the SNP (ordinal: 0, 1, or 2 T alleles), including the main effects in the model; these interaction terms were pooled using meta-analysis.

Meta-analyses were performed using STATA 12 (StataCorp, College Station, Tex.). We considered two-tailed p values <0.05 to be statistically significant.

Sensitivity analyses

We performed several sensitivity analyses. We performed continuous meta-analysis using absolute (percent of fatty acids), rather than study-specific (90th vs. 10th percentile), units. To minimize potential reverse causation due to pre-existing subclinical disease, we excluded cases identified in first 2 years after biomarker sampling. To minimize exposure misclassification due to within-person changes in biomarker levels over time, we censored participants after the first 6 years of follow-up. We performed additional analyses limited to prospective studies only and those without self-reported CHD events.
Results

Characteristics of studies and participants

The 19 studies included 45,637 unique participants from 16 countries including the United States, Australia, Costa Rica, Finland, France, Germany, Ireland, Israel, Italy, Norway, Singapore, the Soviet Union, Spain, Sweden, Switzerland, and the United Kingdom (Table 1; see Online-Only Supplement for details of the participating studies). Most were prospective cohort (n=10 studies) or prospective nested case-control (n=7) studies; 2 were retrospective case-control studies using adipose tissue biomarkers. Biomarker types included phospholipids (plasma or erythrocyte) (n=10), total plasma (n=6), adipose (n=4), and cholesterol esters (n=1); two studies (NHS I and HPFS) measured both total plasma and erythrocyte phospholipids. As expected, omega-3 PUFA concentrations and distributions varied across biomarker types and study assays (eTable 2, eTable 3) with coefficients of variation <10% for most fatty acids and biomarkers (see Online-Only Supplement). For example, median ALA concentrations were generally higher in adipose (0.72% of total fatty acids) than in circulating biomarkers (0.20% of total fatty acids); while EPA, DPA and DHA concentrations were generally higher in phospholipids than other compartments, consistent with prior reports (16, 18).

Median age at baseline was 59 years (range: 18, 97 years), and 62% were male (eTable 4). During a median 10 years of follow-up (range: 1.3, 42), 7973 incident CHD events, 7157 nonfatal MIs, and 2781 fatal CHD events occurred. As not all studies ascertained every exposure and outcome (Table 1), cases of non-fatal MI and fatal CHD do not sum to the number of total CHD cases. Medication use varied across studies; by design, all participants in the analysis were free of prevalent CHD or stroke (eTable 5). Most participants were Caucasian, but CHS and MESA included relatively higher proportions of African-Americans (12.3% and 24.7%,...
respectively); MESA and the Costa Rican adults study included Hispanics (24.9% and 100%, respectively), and MESA and SCHS included Chinese participants (25.0% and 100%, respectively). Across all studies, median BMI was 26 kg/m² and generally up to 30% of participants were current smokers, except for higher rates in SHHEC (44.6%) and ULSAM 50 (51.0%). Alcohol intake was modest, with most participants consuming up to 1 drink/day. Fish oil supplementation was infrequently assessed across studies; use was low (0-4% participants) in 5 of 6 studies with this data (eTable 6); only EPIC-Norfolk had higher prevalence (33%).

EPA, DPA, and DHA and incident CHD

In continuous (per 1 standard deviation increase) multivariable-adjusted analyses, each omega-3 PUFA was associated with about a 9% lower risk of fatal CHD, with RRs (95% CI) for EPA of 0.91 (0.82-1.00); DPA, 0.90 (0.85-0.96); and DHA, 0.90 (0.84-0.96) (Table 2). There was moderate heterogeneity in this association for EPA ($I^2 = 37\%$), and DHA and low heterogeneity for DPA and DHA ($I^2 = 0\%$ and 31%, respectively) (Figure 1). The sum of EPA + DPA + DHA was associated with a 11% lower risk of fatal CHD (eFigure 1). By contrast, none of the long-chain omega-3 PUFA were significantly associated with non-fatal MI. DPA, but not EPA, or DHA, was associated with a significantly lower risk of total CHD, with RRs (95% CI): 0.94(0.90-0.99), 0.94(0.87-0.97), and 0.95(0.91-1.00), respectively (Table 2).

Some differences were observed when EPA, DPA, and DHA were evaluated across quintiles (eTable 7). Upper quintiles of EPA and DHA were associated with a lower risk of non-fatal MI (Quintile 5 vs Quintile 1 comparison: 0.71 (0.56-0.90), 0.87 (0.78-0.97), respectively). Top quintiles of DPA and DHA were associated with a lower risk of fatal CHD (Quintile 5 vs Quintile 1 comparison: 0.76 (0.65-0.90), 0.77 (0.64-0.89), respectively) (Figure 2). Across
biomarker types, inverse associations were generally stronger in the phospholipid and total plasma compartments (Table 2); heterogeneity decreased when adipose tissue and cholesterol ester estimates were excluded from meta-analyses.

**ALA and incident CHD**

In continuous analysis, ALA was associated with a 9% lower risk of fatal CHD: RR (95% CI) 0.91 (0.84-0.98) (Figure 1), but not total CHD or nonfatal MI. For ALA, no single biomarker compartment consistently showed stronger associations across outcomes.

**Restricted cubic spline analysis**

Restricted cubic splines did not identify evidence for nonlinear associations of any of the omega-3 PUFA biomarkers and outcomes in total plasma or phospholipids (p-linearity > 0.05 each; eFigure 2).

**Effect modification**

No significant differences in associations of omega-3 PUFA biomarkers with incident CHD events were observed by age, sex, omega-6 PUFA (LA or AA) concentrations, type 2 diabetes status, statin use, regular aspirin use, year of biomarker sampling, or (for ALA) EPA+DPA+DHA concentrations (p-heterogeneity >0.05 each) (eTable 8). In a post-hoc meta-regression, we observed no significant differences in associations by median length of follow-up (< or ≥10y) (p-heterogeneity >0.05 each). Effect modification was suggested by ethnicity: compared to Caucasians, ALA was associated with significantly lower risk of nonfatal MI among African-Americans (p-heterogeneity=0.001); and for EPA, with significantly lower risk
of total CHD and nonfatal MI among Chinese participants (p-heterogeneity= 0.02 and 0.01, respectively). Among 7 studies with SNP data (eTable 9), no significant interaction was identified by FADS desaturase gene variants (eTable 10).

Sensitivity Analyses

Compared to the main findings, no appreciable differences were observed after excluding cases identified in the first 2 years after biomarker sampling, censoring participants at the first 6 years of follow-up, excluding retrospective studies, or studies with self-reported events (eTable 11). For two studies that analyzed phospholipids in addition to total plasma (NHS I, HPFS), results were similar when phospholipid results from these studies were used in place of total plasma in the meta-analysis (data not shown).
Discussion

In this consortium pooling individual-level harmonized analyses from 19 studies including 45,637 unique participants and nearly 8,000 first CHD events in 16 countries, omega-3 biomarkers ALA, DPA, and DHA were associated with a modestly lower risk of fatal CHD, with EPA showing a trend towards lower risk. The magnitude of observed effect sizes for fatal CHD (~9% per 1 standard deviation increase) are consistent with findings for cardiac death from meta-analyses of trials (8). In contrast, associations with nonfatal MI were generally less robust. Across these diverse studies, findings were consistent by age, sex, omega-6 PUFA LA and AA levels, year of biomarker sampling, presence of absence of diabetes, statin use, and aspirin use. By contrast, effect modification by ethnicity was observed for select exposure-outcome pairings. Separate analyses by biomarker compartment provided further insights, with generally stronger inverse associations in phospholipids and total plasma for EPA, DPA and DHA. This investigation provides the most comprehensive estimates to date of the relationships between seafood and plant-based omega-3 PUFA, assessed using biomarkers, and primary incidence of CHD in generally healthy, free-living populations around the world.

In randomized controlled trials, long-chain omega-3 PUFA benefit multiple major cardiovascular risk factors, including triglyceride levels, blood pressure, heart rate, heart rate variability, endothelial function, and myocardial oxygen demand (1, 10). Compared with many other single nutrients, these demonstrated physiologic benefits provide strong biologic plausibility to support an impact on clinical events. EPA and DHA are also precursors to bioactive lipid metabolites including specialized pro-resolving mediators (SPMs) (18) and CYP450-generated mono-epoxides (MEFAs) (19) that could contribute to lower CHD risk. Our findings are consistent with prior experimental evidence that long-chain n-3 PUFA may have
membrane stabilizing actions in the setting of ischemia-induced ventricular fibrillation (1, 20) and observational evidence showing that benefits of fish consumption are most related to arrhythmic events (21) and fatal CHD (22).

Use of biomarkers allowed separate investigation of each individual omega-3 PUFA. Interestingly, EPA, DPA, and DHA were similarly associated with lower risk of fatal CHD. Biomarker levels of these fatty acids are only moderately interrelated, e.g. r=0.43, 0.51 and 0.13 for EPA and DHA, EPA and DPA, and DPA and DHA, respectively (23). Thus, observed associations for any one of these fatty acids are unlikely to be fully explained by the others. Compared with EPA and DHA, comparatively less is known about the molecular and physiologic effects of DPA; some studies suggest DPA may inhibit ex vivo collagen-stimulated platelet aggregation, thromboxane production, and cyclooxygenase-1 activity (10). In addition, whereas circulating and tissue levels of EPA and DHA are strongly influenced by dietary seafood consumption, DPA concentrations appear to be mainly derived from endogenous elongation of EPA; interconversion between DPA and DHA is very limited (10). Given diverse global dietary sources, effects of ALA on CHD are of particular interest. However, prior reports of dietary and biomarker ALA and CHD risk have been inconsistent (11), perhaps owing to methodologic and analytic differences in these investigations. A key strength of our analysis was the pre-specified, harmonized analytic plan using individual-level data within each study, which allowed consistent assessment of how ALA relates to CHD. In addition, the inclusion of 19 studies minimized the impact of publication bias, wherein studies with positive findings are more likely reported. Compared with prior work (24), we also took advantage of a far larger number of events (e.g., over 4-fold larger for fatal CHD) and observed a similarly lower risk of fatal CHD for ALA as for long-chain omega-3 PUFA. Mechanistically, these
findings are supported by effects of ALA on thrombosis, inflammation, arrhythmia, and endothelial function (25-29). Our findings, combined with relative affordability, global accessibility, and sustainability of ALA (30), support the potential importance of ALA for improving global cardiovascular health.

The large number of cases in our analysis, and inclusion of multiple ethnic subgroups, allowed us to explore potential effect modification in omega-3 PUFA-CHD outcome associations by race/ethnicity. The stronger effects among African-American and Chinese for select n-3-outcome pairings could be due to differences in consumption patterns, true biologic diversity in pathophysiologic pathways, or chance. For instance, preparation methods among Chinese populations could differ from Caucasians, with raw/steamed fish in the former population, vs. more deep fried fish in the latter. Differential pathophysiologic pathways for cardiometabolic risk have also been documented among Asian vs. Caucasian populations; for example, Asians develop type 2 diabetes at a much lower BMI than Caucasians (31,32) and at least three meta-analyses have reported a protective effect of seafood-derived n-3s on incident diabetes among Asians, but not Caucasians (33-35). Finally, our findings of effect modification by race could be due to chance; few studies were available with African-American (n=2 studies: CHS, MESA) and Chinese subgroups (n=2 studies: SCHS, MESA). Our results highlight the need for further work to better understand differences in associations by race for omega-3s and incident CHD phenotypes.

Randomized trials of fish oil supplements have shown mixed effects, although overall pooled findings indicate benefit for lowering risk of cardiac death (8), consistent with our findings. Our investigation tests unique and separate questions from these trials due to differences in omega-3 PUFA source (in our study, dietary; vs. supplements in trials), population
(primary prevention vs. secondary prevention/high risk), and duration (habitual intake vs. short-term supplementation). In cohort-harmonized stratified analyses, we found little evidence for effect modification by statin or aspirin use, which have been hypothesized to reduce benefits of omega-3’s (36). We also found little evidence of effect modification by circulating omega-6 PUFA, LA or AA, which have been hypothesized – but never shown in humans – to reduce cardiovascular benefits of omega-3 PUFA (37). Altogether, our findings suggest that both seafood and plant-derived omega-3 PUFA are beneficial for fatal CHD prevention across diverse population subgroups.

Our stratification by biomarker type provides new insights on which lipid compartments may most influence CHD. Adipose tissue has been suggested for measurement of fatty acids because it reflects long-term dietary intake (~1 yr) (38). Yet, EPA and DHA are more highly concentrated in phospholipids than other compartments, and phospholipids also respond rapidly to dietary changes (39, 40), and may best reflect effects on membrane receptors (1). The best compartment for assessing ALA has also been unclear, with possible advantages to adipose tissue (16) but relatively little prior evaluation of other compartments. Our findings suggest generally stronger inverse associations with CHD for EPA, DPA, and DHA in phospholipids and total plasma, although fewer estimates and cases were available for adipose and cholesterol esters compartments, decreasing precision. Our results support use of phospholipids or total plasma for long-chain omega-3 PUFA exposure, and a need for further investigation of optimal biomarkers for assessing ALA.

Our analysis has several important strengths. Use of biomarkers provided measures of exposure free from recall error, and allowed separate evaluation of different omega-3 PUFA as well as different circulating and tissue lipid compartments. We used standardized definitions and
modeling for the populations, exposures, outcomes, covariates, effect modifiers, and analysis, reducing heterogeneity and potential investigator bias. The majority of studies employed centralized adjudication processes or registry linkage rather than self-report in ascertaining events, reducing information bias. Findings were similar in several sensitivity analyses, suggesting robustness of results to varying assumptions. Our inclusion of all available studies substantially reduces potential for publication bias. The studies included both sexes, multiple races, and a range of socioeconomic statuses across 16 countries, increasing generalizability.

Potential limitations should be considered. Relatively few studies were available for some lipid compartments (e.g., adipose, cholesterol esters), limiting inference for these specific compartments. All cohorts assessed omega-3 PUFA exposure once at baseline; and changes over time would attenuate findings toward the null, causing underestimation of associations. Reduced statistical power in quintile analyses and spline analyses made it difficult to ascertain the specific shape of dose-responses. As we analyzed observational studies, biomarkers and risk factors were not evenly distributed by randomization of study participants and hence, unmeasured or residual confounding cannot be excluded; omega-3 biomarker measures may in part be markers of a long-term healthy lifestyle. However, our findings were independent of a range of major cardiovascular risk factors, and the relative specificity for fatal CHD and known biologic effects of omega-3 PUFA also argues against residual confounding as the sole explanation for our findings. As our findings reflect habitual omega-3 exposure for primary CHD prevention, our results do not imply that fish oil supplementation will necessarily reduce CHD events, particularly in the context of short-term treatment or in those with pre-existing CHD. Both awareness of omega-3 PUFA, laboratory ascertainment methods, and medical treatment of hypertension, hypercholesterolemia, diabetes, angina, and MI have changed over time and could
contribute to heterogeneity of results; however, we observed no significant differences results for studies assaying omega-3 PUFA levels prior to vs. after the year 2000.

In conclusion, our pooled collaboration of global studies using biomarkers of omega-3 PUFA in participants without prevalent CHD shows that habitual consumption of both seafood and plant-based omega-3 PUFA is associated with a modestly lower risk of fatal CHD.
Acknowledgements

Corresponding Author: Dr. Liana Del Gobbo, PhD, Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305 Phone: 857-334-1509, Fax: 617-566-7805, delgobbo@stanford.edu

Author Contributions: Dr. Del Gobbo had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors report substantial contributions to conception or design of the work, or the acquisition, analysis, or interpretation of data for the work; and (2) drafting of the work or revising it critically for important intellectual content; and (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Study concept and design: Mozaffarian, Del Gobbo


Analysis and interpretation of data: Del Gobbo conducted meta-analyses and data analysis for CHS. Aslibekyan performed analysis for the Costa-Rican adults study. Marklund performed analysis for ULSAM 50 and 70. Virtanen performed analysis for KIHD. Wennberg performed analysis for NSHDS I and II. Yakoob performed analysis for NHS I. Chiuve performed analysis for HPFS. dela Cruz performed analysis for MCCS. Frazier-Wood performed analysis for MESA. Guallar performed analysis for EURAMIC. Matsumoto performed analysis for PHS. Prem performed analysis for SCS. Samieri performed analysis for the 3C study. Tanaka performed analysis for InCHIANTI. Wu performed analysis for SHHECS. Zhou performed analysis for ARIC. Imamura performed spline analyses. All authors interpreted data.

Drafting of the manuscript: Del Gobbo, Virtanen, Aslibekyan, Chaves, Fretts, Djoussé, Mozaffarian

Critical revision of the manuscript for important intellectual content: All authors


Study supervision: Mozaffarian

Conflict of Interest Disclosures: Dr. Barberger-Gateau reports grants and non-financial support from Danone Research, Vifor Pharma and Groupe Lipides et Nutrition, personal fees and non-financial support from Nutricia, ILSI Europe and PiLeJe, and a grant from CNIEL (Centre National Interprofessionnel de l'Industrie Laitière). Dr. Del Gobbo reports ad hoc consulting fees from the Life Sciences Research Organization. Dr. Djoussé received investigator-initiated grants from Merck, Amarin Pharma Inc, California Walnut Commission, and NIH. He is also serving as ad hoc consultant for Amarin Pharma Inc. Dr. Helmer received fees for a conference from Novartis. Dr. Mozaffarian reports ad hoc honoraria from Bunge, Pollock Institute, and Quaker Oats; ad hoc consulting for Foodminds, Life Sciences Research Organization, Nutrition Impact, Amarin, Astra Zeneca, Winston and Strawn LLP; membership, Unilever North America Scientific Advisory Board; and chapter royalties from UpToDate. Dr. Psaty serves on the DSMB of a clinical trial for a device funded by the manufacturer (Zoll LifeCor), and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Dr. Woodward
reports consulting fees from Amgen and Novartis, and research funding from Sanofi. No other disclosures were reported.

**Funding/Support:** ARIC was carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN26820110010C, HHSN268201100011C, and HHSN268201100012C, R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.

CHS was supported by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant U01HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The Costa-Rican adult study was supported by grant R01HL081549 from the National Institutes of Health.

EURAMIC was supported by the Commission of the European Communities, as a Concerted Action within Directorate General-XII, with additional support from Directorate General-V Europe against Cancer. The national studies were financed by the Dutch Ministry of Health, Ulster Cancer Foundation and Milk Intervention Board. Grant AKT76 from Cancer Research Switzerland. Swiss National Science Foundation Grant 32-9257-87. Spanish FIS and Ministry of Science and Education, and German Federal Health Office.

EPIC-Norfolk was funded by grants from Medical Research Council and Cancer Research UK. Dr. Imamura also received support from the Medical Research Council Epidemiology Unit Core Support (MC_UU_12015/5).

HPFS was supported by the NIH grants UM1 CA167552, R01 HL35464, AA11181, HL35464, CA55075, HL60712 and P30 DK46200

The InChianti study was supported as a ‘targeted project’ (ICS 110.1\RS97.71) by the Italian Ministry of Health and in part by the Intramural Research Program of the NIH (Contracts N01-AG-916413 and N01-AG-821336 and Contracts 263 MD 9164 13 and 263 MD 821336).

KIND (Kuopio Ischaemic Heart Disease Risk Factor Study) was supported by grants from the Academy of Finland, Helsinki, Finland (grants 41471, 1041086).

MCCS (Melbourne Collaborative Cohort Study) recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database.

MESA and the MESA SHARE project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-
MEHC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-001079, and UL1-TR-000040. Funding for SHARE genotyping was provided by NHLBI Contract N02-HL-64278. Genotyping was performed at Affymetrix (Santa Clara, California, USA) and the Broad Institute of Harvard and MIT (Boston, Massachusetts, USA) using the Affymetrix Genome-Wide Human SNP Array 6.0.

NSHDS I & II (The Northern Sweden Health & Disease Study I & II) was supported by the Swedish Cancer Society and the Swedish Research Council

NHS (Nurses’ Health Study) was supported by research grants UM1 CA186107, R01 CA49449, R01 HL034594, P01CA87969, R01HL034594, and R01HL088521 of the National Institutes of Health

The PHS (Physician’s Health Study) was supported by grant R21 HL088081, CA-34944 and CA-40360, and CA-097193 from the National Cancer Institute and grants HL-26490 and HL-34595 from the National Heart, Lung, and Blood Institute, Bethesda, MD.

The 3C (Three-City) study was conducted under a partnership agreement between the Institut National de la Santé et de la Recherche Médicale (INSERM), the University Bordeaux 2 Victor Segalen and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The Three-City study was also supported by the Caisse Nationale Maladie des Travaillleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Conseils Régionaux d’Aquitaine et Bourgogne, Fondation de France, Ministry of Research-INSERM Programme “Cohortes et collections de données biologiques”, Agence Nationale de la Recherche (grant number COGINUT ANR-06-PNRA-005), the Fondation Plan Alzheimer (grant number FCS 2009-2012), and the Caisse Nationale pour la Solidarité et l’Autonomie (CNSA). Dr Samieri was on a grant from the “Fondation Plan Alzheimer”

SHHEC (Scottish Heart Health Extended Cohort) study was funded by the Scottish Health Department Chief Scientist Organization; British Heart Foundation; FP Fleming Trust. The authors would like to acknowledge Dr. Roger Tavendale for his work with the Scottish Heart Health Study.

SCHS (Singapore Chinese Health Study) was supported by the Singapore National Medical Research Council (grant number: NMRC 1270/2010) and the U.S. NIH (grant numbers: R01CA144034 and UM1 CA182876)

ULSAM 50 and 70 were funded by the Swedish Research Council for Health, Working Life and Welfare (FORTE) Uppsala City Council (ALF) and Swedish Research Council

Role of the Sponsors: The funding sources played no role in the study design and conduct; data collection, management, and analysis; manuscript preparation, review, and approval; or the decision to submit the manuscript for publication.
References


40.) Conquer JA, Holub BJ. Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. *J Lipid Res*. 1998;39:286-292.
Figure Legends

**Figure 1.** Relative risk (RR) of fatal CHD per 1 standard deviation (SD) increase in biomarker (A) alpha-linolenic acid (ALA; 18:3n3), B) eicosapentaenoic acid (EPA; 20:5n3), (C) docosapentaenoic acid, (DPA; 22:5n3), and (D) docosahexaenoic acid (DHA; 22:6n3). Estimates were pooled using random effects meta-analysis.

**Figure 2.** Relative risk (RR) of fatal CHD by quintile (Q) of biomarker alpha-linolenic acid (ALA; 18:3n3), eicosapentaenoic acid (EPA; 20:5n3), docosapentaenoic acid, (DPA; 22:5n3), and docosahexaenoic acid (DHA; 22:6n3). Categorical estimates were pooled using random effects meta-analysis.
### Table 1. Baseline characteristics of 19 studies and 45,637 participants with biomarker measures of omega-3 fatty acids

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Study design</th>
<th>Age, y (mean)</th>
<th>Sex (% male)</th>
<th>Biomarker compartment</th>
<th>Year of blood sampling</th>
<th>Fatty acids assessed</th>
<th>Coronary heart disease (CHD) outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIC</td>
<td>United States</td>
<td>PC</td>
<td>54</td>
<td>48</td>
<td>Plasma phospholipid</td>
<td>1987-1989</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD</td>
</tr>
<tr>
<td>Costa-Rican adults</td>
<td>Costa Rica</td>
<td>RCC</td>
<td>59</td>
<td>72</td>
<td>Adipose tissue</td>
<td>1995-2004</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Nonfatal MI</td>
</tr>
<tr>
<td>CHS</td>
<td>United States</td>
<td>PC</td>
<td>74</td>
<td>40</td>
<td>Plasma phospholipid</td>
<td>1992-1993</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>EPIC-Norfolk</td>
<td>UK</td>
<td>PCC</td>
<td>63</td>
<td>49</td>
<td>Plasma phospholipid</td>
<td>2001-2004</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>EURAMIC</td>
<td>Finland, Norway, Scotland, Ireland, Germany, Switzerland, Spain, Israel, Russia</td>
<td>RCC</td>
<td>54</td>
<td>100</td>
<td>Adipose tissue</td>
<td>1991-1992</td>
<td>ALA, DPA, DHA</td>
<td>Nonfatal MI</td>
</tr>
<tr>
<td>HPFS</td>
<td>United States</td>
<td>PCC</td>
<td>64</td>
<td>100</td>
<td>Total plasma; Erythrocyte phospholipid</td>
<td>1994, 1995</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>InCHIANTI</td>
<td>Italy</td>
<td>PCC</td>
<td>65</td>
<td>45</td>
<td>Total plasma</td>
<td>1998-2000</td>
<td>ALA, EPA, DHA</td>
<td>Total CHD</td>
</tr>
<tr>
<td>KIHD</td>
<td>Finland</td>
<td>PC</td>
<td>52</td>
<td>100</td>
<td>Total plasma</td>
<td>1991-1992</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>MCCS</td>
<td>Australia</td>
<td>PC</td>
<td>56</td>
<td>49</td>
<td>Plasma phospholipid</td>
<td>1990-1994</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Fatal CHD</td>
</tr>
<tr>
<td>MESA</td>
<td>United States</td>
<td>PC</td>
<td>62</td>
<td>47</td>
<td>Plasma phospholipid</td>
<td>2000-2002</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>NSHDS I</td>
<td>Sweden</td>
<td>PCC</td>
<td>55</td>
<td>79</td>
<td>Plasma phospholipid</td>
<td>1995</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD</td>
</tr>
<tr>
<td>NSHDS II</td>
<td>Sweden</td>
<td>PCC</td>
<td>55</td>
<td>62</td>
<td>Plasma phospholipid</td>
<td>2007</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>NHS I</td>
<td>United States</td>
<td>PCC</td>
<td>60</td>
<td>0</td>
<td>Total plasma; Erythrocyte phospholipid</td>
<td>1989-1990, 1989-1990</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>PHS</td>
<td>United States</td>
<td>PCC</td>
<td>69</td>
<td>100</td>
<td>Erythrocyte phospholipid</td>
<td>1995-2000</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>SHHEC</td>
<td>Scotland</td>
<td>PC</td>
<td>49</td>
<td>52</td>
<td>Adipose tissue</td>
<td>1984-1986</td>
<td>DPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>SCHS</td>
<td>Singapore</td>
<td>PCC</td>
<td>66</td>
<td>65</td>
<td>Total plasma</td>
<td>1994-2005</td>
<td>ALA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>3C Study</td>
<td>France</td>
<td>PC</td>
<td>75</td>
<td>39</td>
<td>Total plasma</td>
<td>1999-2000</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD</td>
</tr>
<tr>
<td>ULSAM 50</td>
<td>Sweden</td>
<td>PC</td>
<td>50</td>
<td>100</td>
<td>Cholesterol esters</td>
<td>1970</td>
<td>ALA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
<tr>
<td>ULSAM 70</td>
<td>Sweden</td>
<td>PC</td>
<td>71</td>
<td>100</td>
<td>Adipose tissue</td>
<td>1990</td>
<td>ALA, DPA, EPA, DHA</td>
<td>Total CHD, nonfatal MI, fatal CHD</td>
</tr>
</tbody>
</table>

1. Characteristics described at time of fatty acid biomarker measurement
2. Atherosclerosis Risk in Communities; Costa-Rican adults study; CHS: Cardiovascular Health Study; EPIC-Norfolk: European Prospective Investigation into Cancer (Norfolk); EURAMIC: European study on Antioxidants, Myocardial Infarction and Cancer; HPFS: Health Professionals Follow-up Study; InCHIANTI: Invecchiare in Chianti; KIHD: Kuopio Ischaemic Heart Disease Risk Factor Study; MCCS: Melbourne Collaborative Cohort Study; MESA: Multi-Ethnic Study of Atherosclerosis; NSHDS I & II: Northern Sweden Health & Disease Study I & II; NHS I: Nurses’ Health Study I; PHS: Physicians’ Health Study; SHHEC: Scottish Heart Health Extended Cohort; SCHS: Singapore Chinese Health Study; 3C Study: Three City Study; ULSAM 50 & 70: Uppsala Longitudinal Study of Adult Men
3. PC=prospective cohort; PCC=prospective nested case-control; RCC=retrospective case-control
Table 2. Pooled relative risks (RR) of total CHD, nonfatal MI, and fatal CHD per 1 standard deviation increase in alpha-linolenic acid (ALA; 18:3n3), eicosapentaenoic acid (EPA; 20:5n3), docosapentaenoic acid, (DPA; 22:5n3), and docosahexaenoic acid (DHA; 22:6n3)\(^1\)

<table>
<thead>
<tr>
<th>Exposure</th>
<th>Biomarker</th>
<th>Total CHD</th>
<th>Nonfatal MI</th>
<th>Fatal CHD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>(N) cases(^2)</td>
<td>(N) studies</td>
<td>(RR) (95% CI)</td>
</tr>
<tr>
<td>ALA</td>
<td>Total plasma</td>
<td>2286</td>
<td>6</td>
<td>1.05 (0.91-1.20)</td>
</tr>
<tr>
<td></td>
<td>Phospholipids</td>
<td>3719</td>
<td>7</td>
<td>0.98 (0.92-1.06)</td>
</tr>
<tr>
<td></td>
<td>Adipose tissue</td>
<td>206</td>
<td>1</td>
<td>1.09 (0.74-1.62)</td>
</tr>
<tr>
<td></td>
<td>Cholesterol esters</td>
<td>749</td>
<td>1</td>
<td>1.00 (0.92-1.08)</td>
</tr>
<tr>
<td></td>
<td>Overall</td>
<td>6960</td>
<td>15</td>
<td>1.00 (0.95-1.05)</td>
</tr>
<tr>
<td>EPA</td>
<td>Total plasma</td>
<td>2194</td>
<td>6</td>
<td>0.93 (0.97-1.11)</td>
</tr>
<tr>
<td></td>
<td>Phospholipids</td>
<td>3703</td>
<td>7</td>
<td>0.89 (0.81-0.99)</td>
</tr>
<tr>
<td></td>
<td>Adipose tissue</td>
<td>181</td>
<td>1</td>
<td>1.19 (1.05-1.33)</td>
</tr>
<tr>
<td></td>
<td>Cholesterol esters</td>
<td>749</td>
<td>1</td>
<td>0.97 (0.88-1.07)</td>
</tr>
<tr>
<td></td>
<td>Overall</td>
<td>6827</td>
<td>15</td>
<td>0.94 (0.87-1.02)</td>
</tr>
<tr>
<td>DPA</td>
<td>Total plasma</td>
<td>1412</td>
<td>4</td>
<td>0.93 (0.84-1.02)</td>
</tr>
<tr>
<td></td>
<td>Phospholipids</td>
<td>3703</td>
<td>7</td>
<td>0.92 (0.86-0.97)</td>
</tr>
<tr>
<td></td>
<td>Adipose tissue</td>
<td>1092</td>
<td>2</td>
<td>1.01 (0.94-1.08)</td>
</tr>
<tr>
<td></td>
<td>Cholesterol esters</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Overall</td>
<td>6207</td>
<td>13</td>
<td>0.94 (0.90-0.99)</td>
</tr>
<tr>
<td>DHA</td>
<td>Total plasma</td>
<td>2425</td>
<td>6</td>
<td>0.91 (0.82-1.02)</td>
</tr>
<tr>
<td></td>
<td>Phospholipids</td>
<td>3703</td>
<td>7</td>
<td>0.93 (0.89-0.97)</td>
</tr>
<tr>
<td></td>
<td>Adipose tissue</td>
<td>1096</td>
<td>2</td>
<td>1.05 (0.95-1.16)</td>
</tr>
<tr>
<td></td>
<td>Cholesterol esters</td>
<td>749</td>
<td>1</td>
<td>1.01 (0.93-1.09)</td>
</tr>
<tr>
<td></td>
<td>Overall</td>
<td>7973</td>
<td>16</td>
<td>0.95 (0.91-1.00)</td>
</tr>
</tbody>
</table>

\(^1\)Continuous estimates were pooled using random effects meta-analysis

\(^2\)As not all studies ascertained every exposure and outcome (Table 1), cases of non-fatal MI and fatal CHD do not sum to the number of total CHD cases